

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) announces that on 29 November 2018, the Company granted options (the “**Options**”) to subscribe for a total of 4,200,000 ordinary shares of US\$0.001 each in the share capital of the Company (the “**Share(s)**”) to selected grantees (collectively, the “**Grantees**” and each of them, the “**Grantee**”), subject to acceptance of the Grantees of the Options, under the share option scheme of the Company adopted on 7 December 2015.

Details of the Options are set out below:

<b>Date of grant:</b>	29 November 2018
<b>Total number of Options granted:</b>	4,200,000
<b>Exercise price of the Options granted:</b>	HK\$14.04 per Share
<b>Closing price of the Shares on the date of grant:</b>	HK\$13.88 per Share
<b>The average closing price of the Shares for the five business days immediately preceding the date of grant:</b>	HK\$14.04 per Share

**Validity period of the Options:**

1,200,000 Options:

- (i) 100% of the Options granted to Mr. Pan Yuexin, Mr. Guo Hongxin and Mr. Dai Zumian will be exercisable from 29 November 2018 to 28 November 2023, subject to all the vesting conditions specified by the Board having been satisfied; and

3,000,000 Options:

- (ii) 100% of the Options granted to each remaining Grantee will be exercisable from 29 November 2018 to 28 November 2028 subject to all the vesting conditions specified by the Board having been satisfied.

Among the total of 4,200,000 Options granted, an aggregate of 1,200,000 Options were granted to the following Grantees who are either the Director, chief executive and/or the substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them:

Name of Grantee	Position in the Company	Number of Share Options granted	Approximate % of the issued share capital of the Company as at the date of this announcement
Pan Yuexin 潘躍新	Non-Executive Director	400,000	0.02%
Guo Hongxin 郭宏新	Independent Non-Executive Director	400,000	0.02%
Dai Zumian 戴祖勉	Independent Non-Executive Director	400,000	0.02%

The grant of Options to each of Mr. Pan Yuexin, Mr. Guo Hongxin and Mr. Dai Zumian has been approved by the independent non-executive Directors (excluding the independent non-executive director who is the grantee of the Options) in accordance with Rule 17.04(1) of the Listing Rules.

The granting of 4,200,000 Options to the above Directors has been reviewed and approved by the remuneration committee of the Company.

Save as disclosed above, to the best knowledge, information and belief of the Board, none of the Grantees is a Director, chief executive or substantial shareholder of the Company, or an associate of any of them.

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 30 November 2018

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.*

\* *For identification purposes only*